Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06476938 · ClinicalTrials.gov registry record · NA
Testing Gene PilotLX With Latinx Cancer Patients
A NA study of Cancer, sponsored by Fox Chase Cancer Center.
- Recruiting
- Registry status
- NA
- Development phase
- 232
- Enrollment target
- 4
- Study locations
NCT06476938: Recruiting NA study of Cancer, sponsored by Fox Chase Cancer Center.
NCT06476938 is a NA study of Cancer that is actively recruiting participants, run by Fox Chase Cancer Center. The registered enrollment target is 232 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (93% lower). The trial reports 4 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06476938, a NA study of Cancer, is actively recruiting participants, sponsored by Fox Chase Cancer Center.
- RECRUITING
- Registry status
- NA
- Development phase
- 232 participants
- Enrollment target
- 4
- Study locations
Study Summary
This is a randomized controlled trial designed to evaluate the efficacy of an electronic health decision support tool called Gene PilotLX to increase informed decision making regarding hereditary risk information from tumor genomic profiling (TGP) test among Latinx cancer patients recruited at four cancer centers.
Primary Outcome
PrepDM Scale measures preparedness of patient to make a decision (10 items) regarding a hereditary risk from tumor genomic profiling (TGP) on a 1 "not at all" to 5 "a great deal" scale. Higher means indicated higher perceived level of preparation for decision making.
Conditions Studied
Interventions
- OTHER Gene PilotLX
Study Locations (4)
Pennsylvania
- Fox Chase Cancer Center - Philadelphia
- Temple University Hospital - Philadelphia
New Jersey
- MD Anderson Cancer Center at Cooper - Camden
New York
- Herbert Irving Comprehensive Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 232 participants |
| Start Date | 2025-05-30 |
| Est. Completion | 2027-12-31 |
| Phase | NA |
What NCT06476938 shows while recruiting
NCT06476938 is an interventional study that assigns participants to a tested intervention. The registered 232 participants enrollment target is mid-sized for trials with a published cap, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Cancer appearing as the primary indexed condition, and to 1 intervention - of which Gene PilotLX is the first listed.
NCT06476938 reports a single indexed study location in Pennsylvania, New Jersey, New York.
Frequently Asked Questions
What is clinical trial NCT06476938 about?
NCT06476938 is a clinical study titled "Testing Gene PilotLX With Latinx Cancer Patients". This is a randomized controlled trial designed to evaluate the efficacy of an electronic health decision support tool called Gene PilotLX to increase informed decision making regarding hereditary risk information from tumor genomic profiling (TGP) test among Latinx cancer patients recruited at four ...
What is the current status of trial NCT06476938?
This trial is currently recruiting. It is a NA study. The enrollment target is 232 participants. The study started on 2025-05-30. Estimated completion is 2027-12-31.
What conditions does trial NCT06476938 study?
This clinical trial studies the following conditions: Cancer.
What interventions are being tested in trial NCT06476938?
The interventions under investigation include: Gene PilotLX (OTHER).
Who is sponsoring clinical trial NCT06476938?
This trial is sponsored by Fox Chase Cancer Center, which has 183 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06476938 being conducted?
This trial has 4 study locations across New Jersey, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06476938's enrollment target sits among peer trials
232 219th of 615 higher than 397 of 615 other Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
IMPACT (IMproving Proactive Approaches for Cancer Survivors' Mental Health Treatment)
RECRUITING · NA
-
BfedBwell Optimization Pilot
RECRUITING · NA
-
Legal Evaluation for Greater Access to Cancer Care (LEGAL-CARE)
RECRUITING · NA
-
Optimizing the AYA Survivors' Coping and Emotional Needs Toolkit
RECRUITING · NA
-
Comprehensive Connected Cancer Care (C4): Intervention Evaluation
RECRUITING · NA
-
Cancer-related Fatigue and Its Biological Contributors in Adolescent and Young Adult Brain Tumor Survivors: Effects of a Tele-exercise Intervention
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01356290 · 232 participants · Phase 2
Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors
- NCT04753359 · 232 participants · NA
Mediterranean Diet and Weight Loss: Targeting the Bile Acid/Gut Microbiome Axis to Reduce Colorectal Cancer
- NCT04770870 · 232 participants · NA
Post Approval Study2: Hintermann Series H3 Total Ankle Replacement System
- NCT05948943 · 232 participants · Phase 2
Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI